全文获取类型
收费全文 | 1604349篇 |
免费 | 133889篇 |
国内免费 | 2583篇 |
专业分类
耳鼻咽喉 | 21713篇 |
儿科学 | 53066篇 |
妇产科学 | 46342篇 |
基础医学 | 228465篇 |
口腔科学 | 47588篇 |
临床医学 | 141186篇 |
内科学 | 315610篇 |
皮肤病学 | 34235篇 |
神经病学 | 130552篇 |
特种医学 | 64829篇 |
外国民族医学 | 474篇 |
外科学 | 244499篇 |
综合类 | 39721篇 |
现状与发展 | 3篇 |
一般理论 | 547篇 |
预防医学 | 123381篇 |
眼科学 | 36529篇 |
药学 | 121640篇 |
2篇 | |
中国医学 | 2991篇 |
肿瘤学 | 87448篇 |
出版年
2018年 | 14971篇 |
2016年 | 13053篇 |
2015年 | 15261篇 |
2014年 | 20855篇 |
2013年 | 31666篇 |
2012年 | 43051篇 |
2011年 | 45299篇 |
2010年 | 26561篇 |
2009年 | 25482篇 |
2008年 | 43408篇 |
2007年 | 45597篇 |
2006年 | 46387篇 |
2005年 | 45020篇 |
2004年 | 44390篇 |
2003年 | 42404篇 |
2002年 | 41487篇 |
2001年 | 75797篇 |
2000年 | 78438篇 |
1999年 | 66476篇 |
1998年 | 17750篇 |
1997年 | 16348篇 |
1996年 | 16325篇 |
1995年 | 16031篇 |
1994年 | 15085篇 |
1993年 | 14223篇 |
1992年 | 55472篇 |
1991年 | 53825篇 |
1990年 | 52591篇 |
1989年 | 50868篇 |
1988年 | 47250篇 |
1987年 | 46592篇 |
1986年 | 44311篇 |
1985年 | 42867篇 |
1984年 | 32051篇 |
1983年 | 27579篇 |
1982年 | 16151篇 |
1981年 | 14442篇 |
1980年 | 13571篇 |
1979年 | 30469篇 |
1978年 | 21073篇 |
1977年 | 17771篇 |
1976年 | 16701篇 |
1975年 | 17580篇 |
1974年 | 21498篇 |
1973年 | 20683篇 |
1972年 | 18867篇 |
1971年 | 17779篇 |
1970年 | 16295篇 |
1969年 | 15276篇 |
1968年 | 13958篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
111.
Neurofibromatosis Type 1 Diagnosed in a Child Based on Multiple Juvenile Xanthogranulomas and Juvenile Myelomonocytic Leukemia
下载免费PDF全文
![点击此处可从《Pediatric dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Sune R. R. Jans M.D. Eckhard Schomerus M.D. Anette Bygum M.D. 《Pediatric dermatology》2015,32(1):e29-e32
An association between juvenile xanthogranuloma (JXG), neurofibromatosis type 1 (NF1), and juvenile myelomonocytic leukemia (JMML) has been described in the literature but has only been documented in approximately 20 cases. We diagnosed a patient with NF1 at 25 months of age, before any cutaneous stigmata of this disease had appeared, because we decided to screen for the NF1 gene mutation because of his presentation with multiple JXGs and moderate macrocephaly (2.5 standard deviations) at 9 months of age and JMML diagnosed at 20 months of age. The child is well today after treatment with chemotherapy and allogenic bone marrow transplantation. With increased awareness, patients with JXG and NF1 who develop symptoms possibly related to JMML, such as paleness, skin bleeding, cough, unexplained fever, and hepatosplenomegaly, should be further evaluated. We also emphasize that multiple JXG lesions can be an early marker of NF1. 相似文献
112.
113.
114.
R. E. J. Ryder 《Diabetic medicine》2015,32(3):305-313
On 8 April 2014, a US jury ordered Takeda and Eli Lilly to pay $9 bn in punitive damages after finding that they had concealed the cancer risks associated with pioglitazone. By contrast, on 28 August 2014, the long‐awaited outcome of the 10‐year Kaiser Permanente Northern California study was announced. That study was specifically designed to investigate whether patients exposed to pioglitazone were at an increased risk of bladder cancer and found no association; thus, at last, the controversial issue has been resolved. A review, in retrospect, of the story of the proposed link between pioglitazone and bladder cancer reveals flaws at every stage. In 2012, a BMJ editorial, in keeping with some other contemporary reports, stated ‘it can confidently be assumed that pioglitazone increases the risk of bladder cancer’. Examination of the information which led to such a statement shows that: 1) the pre‐clinical findings of bladder cancer in male rats is not indicative of human risk; 2) there is no association between bladder cancer and pioglitazone in randomized controlled trials, once cases that could not plausibly be related to treatment are removed; and 3) the observational studies that have suggested a link have over‐extrapolated from the data: pioglitazone‐treated patients had more risk factors for bladder cancer than those not treated with pioglitazone. Meanwhile careful study of randomized controlled trials shows evidence of cardiovascular benefit from pioglitazone in Type 2 diabetes, a condition which results, more than anything, in premature cardiovascular death and morbidity. 相似文献
115.
116.
M. Alexandra Friedman Charlotte M. Niznik Janelle R. Bolden Lynn M. Yee 《Journal of community health》2016,41(2):354-358
While peer support has been investigated in multiple clinical contexts, its application to the postpartum setting is unknown. The aim was to assess acceptability of a postpartum peer support program for women with diabetes. Observational survey-based needs assessment of forty low-income women with diabetes, receiving care at a major medical institution. Mean age and gravidity were 30.7 years and 3.15 ± 1.67 respectively. 45 % expressed interest in a “buddy.” There was no significant difference between groups desiring and not desiring this program. A majority of respondents desired telephone, text messaging, and in-person contacts (79.2, 72.1, 83.8 %), with 72.5 % of patients desiring diabetes-related activities during clinic waiting time. Many women desire a postpartum diabetes reciprocal peer program for support outside of clinician visits. Patients are receptive to educational services during their wait and outside of clinic time, a potentially valuable opportunity to share important health information. 相似文献
117.
118.
Turnbull Chris D. Stockley James A. Madathil Shyam Huq Syed S. A. Cooper Brendan G. Ali Asad Wharton Simon Stradling John R. Heitmar Rebekka 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(7):2129-2139
Graefe's Archive for Clinical and Experimental Ophthalmology - Retinal microvascular endothelial dysfunction is thought to be of importance in the development of ocular vascular diseases.... 相似文献
119.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献